SFBN Feed: Star gets $125M Series D as it begins Phase 3 in bleeding disorders https://lnkd.in/gTTaszBv Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
Star Therapeutics raises $125M in Series D for bleeding disorders
This title was summarized by AI from the post below.
More Relevant Posts
-
Yesterday at Fierce Biotech Week, our CEO Alex Zhavoronkov joined Margo Georgiadis (Co-founder & CEO, Montai Therapeutics; Flagship Pioneering) and Christopher Arendt, PhD (Chief Science Officer and Head of Research, Takeda) on the panel “How AI/ML is Accelerating Drug Development.” For Insilico, success in AI drug discovery means cheaper, faster, higher quality drugs, better probability of success, and hopefully higher novelty. #FierceBiotechWeek #GenerativeAI #PharmaAI #DrugDiscovery
-
-
Top LifeSci Startup news featured in our October 7th newsletter: https://lnkd.in/g-WtBqmA MapLight Therapeutics, Inc. Commences IPO; Affinia Therapeutics Raises $40M; Rare Tx Launches; Page Mill Labs Opens #healthcare #biotech #lifescience #HealthTech #AI
-
-
Mills & Reeve's Corporate team has advised Cyclana Bio on £5M pre-seed funding to advance drug discovery for endometriosis 🚀 The new investment will enable the Cambridge-based biotech company to tackle endometriosis through innovative tissue-level therapeutics. It also offers a platform to address other chronic inflammatory diseases. Edward Sloan, head of venture capital investments in Mills & Reeve’s London office, commented: “We are proud to support Cyclana Bio in its journey to bring forward a new generation of therapeutics.” To find out more ➡️ https://lnkd.in/e3uZRmEc #FemHealth #WomensHealth #Innovation #BioTech #TissueTherapeutics #Endometriosis #PreSeedFunding #DrugDiscovery #Corporate
-
Caption 💥 U.S. biotech shows signs of revival. Mirador Therapeutics has raised $400 million in Series B funding, marking one of the largest biotech fundraises of 2025. The company focuses on autoimmune and anti-inflammatory therapies, and this round comes at a critical moment when investor sentiment toward biotech has been subdued for much of the year. 📊 Why it matters: 🔹 Signals renewed investor confidence in the U.S. biotech market 🔹 Positions Mirador as a leader in immunology-focused innovation 🔹 Marks a strong comeback for late-stage private biotech funding 💬 Could this be the start of a biotech funding rebound after months of market slowdown? — ✨ At Life Science Insights 360 (by InCx Insights), we bring you the latest global breakthroughs, funding trends, and innovations shaping the future of life sciences and healthcare. #LifeScienceInsights360 #InCxInsights #Biotech #Pharma #DrugDevelopment #FundingNews #MiradorTherapeutics #LifeSciences #Innovation #HealthcareInvestment #AutoimmuneDisorders #Immunology #BiotechFunding #HealthcareInnovation #GlobalBiotech
-
-
Basking Biosciences Advances Phase 2 Stroke Trial, Unlocks Financing, and Welcomes New CEO We’re excited to share several important milestones at Basking Biosciences: -First patients dosed in Part B of our Phase 2 RAISE trial evaluating BB-031, the first reversible thrombolytic therapy for acute ischemic stroke (AIS). -$27.5 million financing tranche unlocked, supporting execution of Part B and initiation of a planned Phase 1 study of BB-025, BB-031’s rapid-onset reversal agent. -Julia Owens, Ph.D., appointed CEO, bringing deep experience in biotech company building and drug development as Basking enters its next stage of growth. Read the full announcement here: https://lnkd.in/gycRkScC #Stroke #Biotech #ClinicalTrials #Innovation #BaskingBiosciences
-
-
SFBN Feed: Expedition resupplies for phase 2 COPD voyage with $165M series A https://lnkd.in/g8VBrnJn Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures [...] #BayArea #SanFrancisco #Biotech #Lifescience #News
-
#BiOFUNDING 💡 Riltide Medicines Closes Multi-Million RMB Seed Round On October 20, Riltide Medicines announced the completion of its multi-million RMB seed financing, led by NRL Capital with Qingtan Investment joining as a co-investor. The funding will be primarily used to: 🔬 Advance preclinical development of Riltide’s core pipeline 🤖 Build and enhance the AI-driven interactive molecular design platform This marks a key milestone in accelerating innovative drug discovery. #RiltideMedicines #SeedFunding #Biotech #DrugDiscovery #AIinPharma #LifeSciences #PharmaceuticalInnovation #PreclinicalResearch #VentureCapital #HealthTech #MolecularDesign
-
-
🎉 Excited to announce that SR One co-led the $205M Series A for Crystalys Therapeutics alongside Novo Holdings and Catalys Pacific Crystalys is advancing dotinurad, a next-generation gout therapy already approved and treating 1.2M+ patients across several countries in Asia, through global Phase 3 trials to address critical unmet needs in the US and Europe. Proud to support this experienced team led by James Mackay, Ph.D. as they bring better treatment options to patients. #Biotech #VentureCapital #SROne
-
This week on the Business of Biotech, Daniel Teper, founder and CEO of NAYA Therapeutics, joined me in Miami to talk about the astatine-211 isotope and radiopharmaceuticals, decentralized manufacturing, his plans to conduct clinical trials in China, the funding climate for early stage biotech, and what's happening in the South Florida biotech ecosystem. To watch the full episode, click the link in the comments 👇
